Recent FDA approvals and changes.
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017277:Drug Approval; D004338:Drug Combinations; D016568:Drugs, Generic / Q000627:therapeutic use*; D015483:HIV Antibodies / Q000097:blood*; D016655:HIV Core Protein p24 / Q000097:blood*; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy; D015497:HIV-1 / Q000276:immunology / Q000302:isolation & purification; D015498:HIV-2 / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D019829:Nevirapine / Q000627:therapeutic use; D011933:Reagent Kits, Diagnostic; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004338:Drug Combinations; D016568:Drugs, Generic; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D011933:Reagent Kits, Diagnostic; D018894:Reverse Transcriptase Inhibitors; D013607:Tablets; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine